Sensitive on-site detection of SARS-CoV-2 by ID NOW COVID-19

Eva Krause; Andreas Puyskens; Daniel Bourquain; Annika Brinkmann; Barbara Biere; Lars Schaade; Janine Michel; Andreas Nitsche

doi:10.1016/j.mcp.2021.101742

Sensitive on-site detection of SARS-CoV-2 by ID NOW COVID-19

Mol Cell Probes. 2021 Aug:58:101742. doi: 10.1016/j.mcp.2021.101742. Epub 2021 May 8.

Authors

Eva Krause¹, Andreas Puyskens¹, Daniel Bourquain¹, Annika Brinkmann¹, Barbara Biere², Lars Schaade¹, Janine Michel¹, Andreas Nitsche³

Affiliations

¹ Centre for Biological Threats and Special Pathogens - Highly Pathogenic Viruses (ZBS 1), Robert Koch Institute, Seestraße 10, 13353 Berlin, Germany.
² Influenza and Other Respiratory Viruses (FG 17), Robert Koch Institute, Seestraße 10, 13353 Berlin, Germany.
³ Centre for Biological Threats and Special Pathogens - Highly Pathogenic Viruses (ZBS 1), Robert Koch Institute, Seestraße 10, 13353 Berlin, Germany. Electronic address: NitscheA@rki.de.

Abstract

Point of care detection of SARS-CoV-2 is one pillar in a containment strategy and important to break infection chains. Here we report the sensitive, specific and robust detection of SARS-CoV-2 and respective variants of concern by the ID NOW COVID-19 device.

Keywords: COVID-19; Diagnostics; On-site detection; SARS CoV-2.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

COVID-19 / diagnosis*
COVID-19 / virology
COVID-19 Testing / methods*
Clinical Laboratory Techniques / methods
Humans
Molecular Diagnostic Techniques / methods*
Point-of-Care Systems*
Reproducibility of Results
SARS-CoV-2 / genetics*
SARS-CoV-2 / physiology
Sensitivity and Specificity